The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Atara Biotherapeutics's Revenue for the
three
months ended in Mar. 2026 was $0.52 Mil. Atara Biotherapeutics's average Accounts Receivable for the
three
months ended in Mar. 2026 was $1.25 Mil.
Hence, Atara Biotherapeutics's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.41.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Atara Biotherapeutics Receivables Turnover Related Terms
Atara Biotherapeutics Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Atara Biotherapeutics's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ATRA vs ANIX, BMEA, PMN: Receivables Turnover Comparison
For the Biotechnology subindustry, Atara Biotherapeutics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Atara Biotherapeutics Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Atara Biotherapeutics's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Atara Biotherapeutics's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Atara Biotherapeutics (ATRA) has a Receivables Turnover of 0.41 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Atara Biotherapeutics and its competitors. According to the industry distribution chart, Atara Biotherapeutics ranks #303 out of 840 companies in the Biotechnology industry, placing it in the top 36.1%.
Is Atara Biotherapeutics' Receivables Turnover too high?
Atara Biotherapeutics' current Receivables Turnover is 0.41. The Biotechnology industry median Receivables Turnover is 5.30. Atara Biotherapeutics' value of 0.41 is 92.3% below this industry median. Based on the distribution chart, Atara Biotherapeutics ranks #303 out of 840 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Atara Biotherapeutics has a GF Score™ of 31/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Atara Biotherapeutics' Receivables Turnover compare to ANIX and BMEA?
According to the Biotechnology industry distribution chart, Atara Biotherapeutics ranks #303 out of 840 companies for Receivables Turnover. This puts Atara Biotherapeutics in the upper half of its industry. The industry median Receivables Turnover is 5.30. Atara Biotherapeutics' value of 0.41 is 92.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.30, based on 840 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Atara Biotherapeutics's current Receivables Turnover of 0.41 is 92.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Atara Biotherapeutics and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Atara Biotherapeutics's current Receivables Turnover is 0.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atara Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Atara Biotherapeutics (ATRA) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.55, compared to a current price of $9.72 — trading 527.1% above its estimated fair value. The current Receivables Turnover is 0.41 and 92.3% below the Biotechnology industry median of 5.30. Atara Biotherapeutics' overall GF Score™ is 31/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Atara Biotherapeutics (ATRA), the current Receivables Turnover is 0.41 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Atara Biotherapeutics (ATRA) Overvalued in 2026?
Based on GuruFocus' analysis, Atara Biotherapeutics stock appears to be overvalued.
The current stock price of $9.72 is trading 527.1% above its estimated GF Value™ of $1.55.
GuruFocus considers Atara Biotherapeutics to be Significantly Overvalued.
Key valuation signals for ATRA:
Receivables Turnover: 0.41
GF Value™: $1.55 vs. price of $9.72 (527.1% above fair value)
Industry Position: 92.3% below the Biotechnology median (#303 of 840)
No single metric tells the full story. See the ATRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.
31GF Score
Get the complete analysis for ATRA
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ATRA has been successfully added to your 
